Posted on

Lung Transplant After COVID-19: What Patients Need to Know

Loading

“COVID-19 is a complex disease. In some people, it can be a mild respiratory illness that is easy to recover from. In others, it can be severe and lead to a lengthy hospital stay. Patients with severe COVID-19 might need intensive care and a ventilator to help them breathe.

For people with severe illness, sometimes the only life-saving option is a lung transplant. As a pulmonologist who specializes in caring for both patients with severe COVID-19 and those who receive a transplant, I’ve seen firsthand the difference a lung transplant can make.

Here’s what our expert lung transplant team at the Temple Lung Center knows about performing these critical procedures”

Learn more here.

Loading
Posted on

COVID-19 and Heart Failure

Loading

COVID-19 restrictions are easing. What does that mean for heart failure patients?

Although the coronavirus is still a major health threat, restrictions are easing across the nation. That leaves many people— including heart failure patients — wondering if it’s safe to go out in public and get back to a normal routine. 

The most important thing to remember is that people with heart disease, including heart failure, are at risk of getting much sicker or even dying if they get COVID-19.  So if you have a history of heart disease or have a risk factor for heart disease or stroke, stay informed and stay cautious. 

Learn more here.

Loading
Posted on

She Died With Long Covid. Should Her Organs Have Been Donated?

Loading

“Covid-19 ravaged Heidi Ferrer’s body and soul for over a year, and in May the “Dawson’s Creek” screenwriter killed herself in Los Angeles. She had lost all hope.

“I’m so sorry,” she said in a goodbye video to her husband and son. “I would never do this if I was well. Please understand. Please forgive me.”

Her husband, Nick Guthe, a writer and director, wanted to donate her body to science. But the hospital said it was not his decision to make because Ms. Ferrer, 50, had signed up to be an organ donor. So specialists recovered several organs from the body before disconnecting her from a ventilator.”

Read full story, here.

Loading
Posted on

Dialysis Patients Mount Best COVID Vax Response After Third Dose

Loading

“Even people with end-stage renal disease (ESRD) were able to bolster an immune response to the COVID-19 vaccine, researchers reported.

According to a systematic review and meta-analysis of 32 studies, the overall immunogenicity rate for people on dialysis was 86% (95% CI 81-89), noted Chih-Hsiang Chang, MD, of Chang Gung Memorial Hospital in Linkou, Taiwan, and colleagues in JAMA Network Open.

After the first vaccination dose, those on dialysis saw an immune response rate of 41% (95% CI 32-52, I2=87.3%), which subsequently jumped to 89% (95% CI 85-91, I2=66.7%) after the second dose.”

Read more here.

Loading
Posted on

CDC: Some Immunocompromised People Can Get a Fourth Dose

Loading

“Moderately or severely immunocompromised” adults ages 18 and up who received an additional dose of Pfizer or Moderna’s mRNA vaccines may now receive a booster dose of Pfizer, Moderna, or Johnson & Johnson at least 6 months after completing their third dose, the agency said.

They added that if a moderate to severely immunocompromised adult has received a two-dose series of Pfizer or Moderna, and more than 28 days has elapsed, that person should “immediately” receive an additional dose of Pfizer or the full-dose volume of 100 μg for Moderna, followed by a single booster dose with any of the three authorized vaccines at least 6 months later.”

Read more, here.

Loading
Posted on

FDA Greenlights ‘Mix and Match’ COVID Boosters

Loading

“The FDA authorized booster doses of Moderna and Johnson & Johnson’s COVID-19 vaccines and also authorized a “mix and match” or heterologous approach to boosters for all three available vaccines (including Pfizer’s) in the indicated populations, the agency announced on Wednesday.

Ultimately, the FDA went with what was recommended by their advisory panel, the Vaccines and Related Biological Products Advisory Committee (VRBPAC), which voted for a half-dose Moderna booster in adults ages 65 and up, adults ages 18-64 at high risk of severe COVID, and adults 18-64 with frequent occupational and institutional exposure to SARS-CoV-2, at least 6 months after completing the primary series.”

Learn more here.

Loading
Posted on

Preparing for the flu season during COVID-19

Loading

It’s important to get your flu vaccine because the flu and coronavirus disease 2019 (COVID-19) may be circulating at the same time and cause similar symptoms.

Learn more about the similarities and differences of COVID-19 and the flu.

The flu vaccine doesn’t protect you from COVID-19. But the flu vaccine could reduce flu symptoms that could be confused with COVID-19 symptoms. The flu vaccine can also help lessen the impact on health care providers and hospitals by reducing the number of people with severe flu and hospitalized with the flue.

Read more here.

Loading
Posted on

The Science Supporting the U.S. Case for COVID Boosters

Loading

“U.S. health officials laid out the scientific rationale for a third dose of the COVID-19 mRNA vaccines for all U.S. adults on Wednesday, relying on published and unpublished CDC data, as well as a preprint study.

Overall, they said that there is evidence that vaccine effectiveness against infection — both symptomatic and asymptomatic — has been decreasing over time, but that protection against severe disease, hospitalization, and death remains relatively high.

In anticipation of further waning of immunity amid the ongoing Delta variant-fueled surge — which is posing additional challenges — pulling the trigger on booster shots could help the U.S. stay ahead of the virus, they said.”

Read more, here.

Loading
Posted on

Pfizer-BioNTech COVID-19 vaccine becomes first to win FDA’s full approval, paving way for boosters, mandates

Loading

“Eight months after authorizing the Pfizer-BioNTech COVID-19 vaccine for emergency use in the USA, the Food and Drug Administration issued its full stamp of approval.

Now that the companies’ detailed, so-called biologics license application has been granted, it’s likely that vaccination will be required by many companies, schools and other entities. 

Monday, President Joe Biden called on companies, nonprofit groups, government agencies and schools to “step up vaccine requirements that will reach millions more people.” 

Vaccinations allowed people in this country to stop worrying about diseases such as smallpox, polio, measles, mumps and rubella, he said, and vaccines can help do the same for COVID-19.”

Read more, here.

Loading
Posted on

NIH launches study of third COVID-19 vaccine dose in kidney transplant recipients

Loading

“A pilot study has begun to assess the antibody response to a third dose of an authorized COVID-19 mRNA vaccine in kidney transplant recipients who did not respond to two doses of the Moderna or Pfizer-BioNTech COVID-19 vaccine. The Phase 2 trial is sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The lifelong immunosuppressive therapy that organ transplant recipients must take to prevent organ rejection blunts their immune response to both pathogens and vaccines. Research has shown that many organ transplant recipients do not develop antibodies against SARS-CoV-2, the virus that causes COVID-19, after receiving an authorized COVID-19 vaccine regimen. The purpose of the new study is to determine whether a third dose of one of the mRNA COVID-19 vaccines could overcome this problem for at least some kidney transplant recipients. This is particularly important because this population has a high prevalence of conditions that are risk factors for severe COVID-19, such as cardiovascular disease and diabetes.”

Read more, here.

Loading